6
ALL6
Bridge BiotherapeuticsYear
6
ALL3
20242
20231
2020DEALS // DEV.
6
ALL3
Deals3
DevelopmentsCountry
6
ALL6
SOUTH KOREA6
ALL1
Boehringer Ingelheim GmbH1
Emory University School of Medicine3
Inapplicable1
University of Colorado School of MedicineTherapeutic Area
6
ALL2
Oncology4
Pulmonary/Respiratory DiseasesStudy Phase
6
ALL4
Phase II2
PreclinicalDeal Type
6
ALL2
Collaboration3
Inapplicable1
TerminationProduct Type
6
ALL6
Other Small MoleculeDosage Form
6
ALL6
Oral CapsuleLead Product
6
ALL6
BBT-877Target
6
ALL6
AutotaxinLead Product(s) : BBT-877,Pirfenidone
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bridge Biotherapeutics Completes Enrollment in Phase 2a Study of BBT-877 for IPF
Details : BBT-877 a novel autotoxin (ATX) inhibitor, small molecule drug candidate which is currently being evaluated for the treatment of idiopathic pulmonary fibrosis.
Product Name : BBT-877
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 29, 2024
Lead Product(s) : BBT-877,Pirfenidone
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BBT-877,Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Emory University School of Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
Bridge Biotherapeutics Launches Collaboration with Emory To Explore BBT-877 Therapy
Details : A collaboration will assess BBT-877, an ATX inhibitor, combined with anti-PD-1 immunotherapy for NSCLC patients with KRAS and P53 mutations resistant to treatment.
Product Name : BBT-877
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 28, 2024
Lead Product(s) : BBT-877,Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Emory University School of Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : BBT-877
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : University of Colorado School of Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
Bridge Biotherapeutics Announces Research Collaboration with University Of Colorado
Details : The collaboration focuses on BBT-877, an immuno-oncology cancer treatment, conducting preclinical studies to evaluate its potential in enhancing anti-tumor immunity.
Product Name : BBT-877
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 26, 2024
Lead Product(s) : BBT-877
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : University of Colorado School of Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : BBT-877
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BBT-877 is an orally administered autotaxin enzyme inhibitor which is under development as a treatment for various fibrotic diseases such as idiopathic pulmonary fibrosis (IPF).
Product Name : BBT-877
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 04, 2023
Lead Product(s) : BBT-877
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BBT-877
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BBT-877 is an orally administered autotaxin enzyme inhibitor which is under development as a treatment for various fibrotic diseases such as idiopathic pulmonary fibrosis (IPF).
Product Name : BBT-877
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 25, 2023
Lead Product(s) : BBT-877
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BBT-877
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Boehringer Ingelheim GmbH
Deal Size : Undisclosed
Deal Type : Termination
Details : Bridge Biotherapeutics and Boehringer Ingelheim have mutually agreed on the termination of the Collaboration and License Agreement entered into in July 2019 to develop BBT-877 for the treatment of idiopathic pulmonary fibrosis and various fibrotic diseas...
Product Name : BBT-877
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 11, 2020
Lead Product(s) : BBT-877
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Boehringer Ingelheim GmbH
Deal Size : Undisclosed
Deal Type : Termination